Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

被引：135

作者：

Allred, D. Craig ^{[1
]}

机构：

[1] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA

来源：

MODERN PATHOLOGY | 2010年 / 23卷

关键词：

breast cancer; immunohistochemistry; estrogen receptor; progesterone receptor; HER2; CENTRALLY REVIEWED EXPRESSION; TAMOXIFEN ADJUVANT THERAPY; IN-SITU HYBRIDIZATION; LIGAND-BINDING ASSAY; ENDOCRINE THERAPY; PREDICTING RESPONSE; PROGNOSTIC-FACTORS; AMERICAN-SOCIETY; SYSTEMIC THERAPY; TARGETED THERAPY;

D O I：

10.1038/modpathol.2010.55

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ER alpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERa, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies. Modern Pathology (2010) 23, S52-S59; doi:10.1038/modpathol.2010.55

引用

页码：S52 / S59

页数：8

共 82 条

[81] When is a tumor marker ready for prime time?: A case study of c-erbB-2 as a predictive factor in breast cancer [J].

Yamauchi, H ;

Stearns, V ;

Hayes, DF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2334-2356

[82] HER-2 testing in breast cancer using parallel tissue-based methods [J].

Yaziji, H ;

Goldstein, LC ;

Barry, TS ;

Werling, R ;

Hwang, H ;

Ellis, GK ;

Gralow, JR ;

Livingston, RB ;

Gown, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1972-1977

← 1 2 3 4 5 6 7 8 9 →